GENFIT S.A. AND THE BANK OF NEW YORK MELLON As Depositary AND OWNERS AND HOLDERS OF AMERICAN DEPOSITARY SHARES Deposit AgreementDeposit Agreement • March 14th, 2019 • Genfit S.A. • Biological products, (no disgnostic substances) • New York
Contract Type FiledMarch 14th, 2019 Company Industry JurisdictionDEPOSIT AGREEMENT dated as of , 2019 among GENFIT S.A., a company incorporated under the laws of France (herein called the Company), THE BANK OF NEW YORK MELLON, a New York banking corporation (herein called the Depositary), and all Owners and Holders (each as hereinafter defined) from time to time of American Depositary Shares issued hereunder.
UNDERWRITING AGREEMENTUnderwriting Agreement • March 14th, 2019 • Genfit S.A. • Biological products, (no disgnostic substances) • New York
Contract Type FiledMarch 14th, 2019 Company Industry Jurisdiction
ContractGenfit S.A. • December 17th, 2021 • Biological products, (no disgnostic substances)
Company FiledDecember 17th, 2021 IndustryGENFIT: Ipsen and GENFIT enter into exclusive licensing agreement for elafibranor, a Phase III asset evaluated in Primary Biliary Cholangitis, as part of a long-term global partnership
ContractShare Purchase Agreement • April 18th, 2023 • Genfit S.A. • Biological products, (no disgnostic substances)
Contract Type FiledApril 18th, 2023 Company IndustryCertain information has been excluded from this agreement (indicated by “[***]”) because such information (i) is not material and (ii) would be competitively harmful if publicly disclosed.
COLLABORATION AND LICENSE AGREEMENTCollaboration and License Agreement • May 27th, 2020 • Genfit S.A. • Biological products, (no disgnostic substances) • New York
Contract Type FiledMay 27th, 2020 Company Industry JurisdictionThis Collaboration and License Agreement (the “Agreement”) is entered into as of June 24, 2019 (the “Effective Date”) by and between Genfit SA, a corporation organized and existing under the laws of France and having a place of business at Parc Eurasanté, 885 avenue Eugène Avinée, 59120 Loos, France (“Genfit”), and Terns Pharmaceutical, Inc., an exempted company organized and existing under the laws of the Cayman Islands and having a place of business at P. O. Box 613, Harbor Center, George Town, Grand Cayman KY1-1107, Cayman Islands (“Terns”). Genfit and Terns are sometimes referred to herein individually as a “Party” and collectively as the “Parties.”